EGFR and non-small cell lung carcinoma: Taken together, these results suggest that EGFR signaling partially contributed to the difference between gefitinib-sensitive PC9 and resistant PC9/gef cells and hint at the existence of an alternative activated signaling pathway, which may play an essential role in the development of TKI resistance in NSCLC cells.